Featured Research

from universities, journals, and other organizations

Patients at high risk of recurrences of heart disease: Breakthrough in prevention

Date:
May 24, 2010
Source:
University of Montreal
Summary:
Researchers have announced promising findings of a major clinical study study on VIA-2291 -- a recently developed medication that can effectively reduce inflammation, which can contribute to the formation and progression of atherosclerosis plaque and infarct.

Researchers have announced promising findings of a major clinical study study on VIA-2291 -- a medication developed by Via Pharmaceuticals, a San Francisco-based biotechnology firm, that can effectively reduce inflammation, which can contribute to the formation and progression of atherosclerosis plaque and infarct.

Related Articles


The results of the study, carried out at the Montreal Heart Institute (MHI) by Dr. Jean-Claude Tardif, are now available in the journal Circulation Cardiovascular Imaging. Dr. Tardif is a cardiologist and director of the MHI Research Centre, as well as a professor in the faculty of medicine and holder of the atherosclerosis research chair at the Université de Montréal.

"Up to now, standard treatments for patients with acute coronary syndrome (unstable angina and infarct) have not specifically reduced inflammation, an important component of atherosclerosis. However, research in recent years has allowed us to determine that the presence of inflammation significantly increases the risk of recurrence among these patients. The clinical study was conducted with about 200 patients, and the findings we're publishing show that VIA-2291 may finally offer the solution we need to target and reduce inflammation. In fact, these newly published data strongly support the evaluation of VIA-2291 in larger outcome trials," said Dr. Tardif.

The Montreal Heart Institute's Research Centre directed the study in several hospitals in Canada and the United States as well as analyzed all of the data, including data collected by CAT scans of coronary arteries.

"The publication of this new study attests once again to the excellence of the entire team at the Montreal Heart Institute's Research Centre. While we're clearly satisfied with the findings obtained with VIA-2291, we're even more thrilled at the prospect of taking a big step toward more effective and personalized prevention of cardiovascular disease," concluded Dr. Tardif.


Story Source:

The above story is based on materials provided by University of Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jean-Claude Tardif, Philippe L. L'Allier, Reda Ibrahim, Jean C. Grégoire, Anna Nozza, Mariève Cossette, Simon Kouz, Marc-André Lavoie, Janie Paquin, Tilmann M. Brotz, Rebecca Taub, and Josephine Pressacco. Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome. Circulation Cardiovascular Imaging, 2010; 3: 298-307 DOI: 10.1161/CIRCIMAGING.110.937169

Cite This Page:

University of Montreal. "Patients at high risk of recurrences of heart disease: Breakthrough in prevention." ScienceDaily. ScienceDaily, 24 May 2010. <www.sciencedaily.com/releases/2010/05/100520141242.htm>.
University of Montreal. (2010, May 24). Patients at high risk of recurrences of heart disease: Breakthrough in prevention. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2010/05/100520141242.htm
University of Montreal. "Patients at high risk of recurrences of heart disease: Breakthrough in prevention." ScienceDaily. www.sciencedaily.com/releases/2010/05/100520141242.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins